Amanote Research
Register
Sign In
Letter: Immunogenicity of Infliximab Originator vs. CT-P13 in IBD Patients-Authors’ Reply
Alimentary Pharmacology and Therapeutics
- United Kingdom
doi 10.1111/apt.14274
Full Text
Open PDF
Abstract
Available in
full text
Categories
Hepatology
Pharmacology
Gastroenterology
Date
October 11, 2017
Authors
Y. Komaki
A. Yamada
F. Komaki
A. Sakuraba
Publisher
Wiley
Related search
Letter: Immunogenicity of Infliximab Originator vs. CT-P13 in IBD Patients
Alimentary Pharmacology and Therapeutics
Hepatology
Pharmacology
Gastroenterology
Letter: Immunogenicity of Anti-TNF in Elderly IBD Patients-Authors' Reply
Alimentary Pharmacology and Therapeutics
Hepatology
Pharmacology
Gastroenterology
Editorial: Antigenic Response to CT-P13 and Infliximab Originator in IBD Shows Similar Epitope Recognition-Evidence From Basic Science Supports Safe Switching to Biosimilars. Authors’ Reply
Alimentary Pharmacology and Therapeutics
Hepatology
Pharmacology
Gastroenterology
Letter: Immunogenicity of Anti-TNF in Elderly IBD Patients
Alimentary Pharmacology and Therapeutics
Hepatology
Pharmacology
Gastroenterology
Letter: Infliximab Therapy for Patients With Inflammatory Bowel Disease - Some Unanswered Questions. Authors’ Reply
Alimentary Pharmacology and Therapeutics
Hepatology
Pharmacology
Gastroenterology
Letter: Predicting Azathioprine-Associated Pancreatitis in IBD-phenotype or Genotype? Authors' Reply
Alimentary Pharmacology and Therapeutics
Hepatology
Pharmacology
Gastroenterology
Editorial: Which Iron Preparation for Patients With IBD? Authors’ Reply
Alimentary Pharmacology and Therapeutics
Hepatology
Pharmacology
Gastroenterology
Letter: Elderly AIH Patients-An Important Subgroup. Authors’ Reply
Alimentary Pharmacology and Therapeutics
Hepatology
Pharmacology
Gastroenterology
Letter: Limitations of Defecography Among Patients With Refractory Constipation. Authors' Reply
Alimentary Pharmacology and Therapeutics
Hepatology
Pharmacology
Gastroenterology
